Literature DB >> 26139389

Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study).

Inger Camilla Solberg1, Marte Lie Høivik, Milada Cvancarova, Bjørn Moum.   

Abstract

OBJECTIVES: Identifying ulcerative colitis (UC) patients with increased risk of colectomy is essential for appropriate treatment. We aimed to develop a prediction model assessing the risk of having colectomy within the first 10 years after diagnosis.
MATERIAL AND METHODS: A population-based inception cohort of UC patients diagnosed in south-eastern Norway between 1990 and 1994 has been followed for 10 years. Altogether 519 patients were recruited including 49 patients who were colectomized. Based on the best-fitted multivariate model, the probabilities of colectomy were computed for selected levels of baseline covariates, and the results arranged in a prediction matrix. The following risk factors at diagnosis were analyzed: age, smoking, sex, disease extent, weight loss and fever and need for systemic steroids. Biochemical markers included C-reactive protein (CRP, <30 or ≥30 mg/l); erythrocyte sedimentation rate (ESR, <30 or ≥30 mm/h) and hemoglobin (Hgb, <10.5 or ≥ 10.5 g/dL).
RESULTS: Extent of disease, age (<40 years, ≥40 years), need for systemic steroids and CRP or ESR (<30 or ≥30) at diagnosis were independently associated with colectomy and were combined in a prediction matrix. The probabilities of colectomy during the follow-up period ranged from 2.6% to 40.1% depending on the combination of predictors at diagnosis.
CONCLUSIONS: Our prediction model revealed significant differences in the probability of undergoing colectomy during a 10-years course of disease, which supports an early individualized treatment approach in UC.

Entities:  

Keywords:  colectomy; population-based; prognosis; risk factors; ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 26139389     DOI: 10.3109/00365521.2015.1064991

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

Review 1.  Oral pathology in inflammatory bowel disease.

Authors:  Miranda Muhvić-Urek; Marija Tomac-Stojmenović; Brankica Mijandrušić-Sinčić
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 2.  New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.

Authors:  Edward L Barnes; Robert Burakoff
Journal:  Inflamm Bowel Dis       Date:  2016-12       Impact factor: 5.325

Review 3.  Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases.

Authors:  Roberta Caccaro; Imerio Angriman; Renata D'Incà
Journal:  World J Gastrointest Surg       Date:  2016-03-27

Review 4.  Contemporary Management of Ulcerative Colitis.

Authors:  Rohini Vanga; Millie D Long
Journal:  Curr Gastroenterol Rep       Date:  2018-03-27

Review 5.  Disease monitoring strategies in inflammatory bowel diseases: What do we mean by "tight control"?

Authors:  Lorant Gonczi; Talat Bessissow; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2019-11-07       Impact factor: 5.742

6.  Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.

Authors:  Millie D Long; Timothy W Smith; Marco Dibonaventura; David Gruben; Danielle Bargo; Leonardo Salese; Daniel Quirk
Journal:  Inflamm Bowel Dis       Date:  2020-05-12       Impact factor: 5.325

Review 7.  Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies.

Authors:  Iril Monstad; Oistein Hovde; Inger Camilla Solberg; Bjørn A Moum
Journal:  Ann Gastroenterol       Date:  2014

Review 8.  Inflammatory bowel disease: towards a personalized medicine.

Authors:  Mathurin Flamant; Xavier Roblin
Journal:  Therap Adv Gastroenterol       Date:  2018-01-10       Impact factor: 4.409

Review 9.  Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.

Authors:  Jason Reinglas; Lorant Gonczi; Zsuzsanna Kurt; Talat Bessissow; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2018-08-28       Impact factor: 5.742

10.  Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis.

Authors:  Jon R Florholmen; Kay-Martin Johnsen; Renate Meyer; Trine Olsen; Øystein K Moe; Petter Tandberg; Mona D Gundersen; Jan-Magnus Kvamme; Knut Johnsen; Terje Løitegård; Gabriele Raschpichler; Cecilia Vold; Sveinung W Sørbye; Rasmus Goll
Journal:  BMC Gastroenterol       Date:  2020-10-02       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.